Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 2, 2026, covering a share repurchase executed on February 27, 2026. GSK is a global biopharma company headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow) for a reporting period.
- Shares Purchased: 430,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,153.00p; highest price paid was 2,197.00p.
- Volume-Weighted Average Price (VWAP): 2,179.36p.
- Broker: BNP Paribas SA.
- Treasury Shares Held: Following this purchase, GSK holds 244,027,094 ordinary shares in treasury.
- Shares in Issue: 4,072,135,394 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.99% of total voting rights.
Material Changes and Program Status
This purchase is part of GSK's existing buyback programme, executed pursuant to a non-discretionary agreement with the broker announced on February 17, 2026. Since the start of this agreement on February 17, 2026, the company has purchased a total of 4,136,000 ordinary shares. The filing does not disclose material changes to revenue, profit, or debt levels, as it is a transaction report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025.
Key Facts for Investor Verification
- Verify the total remaining authorization under the existing buyback programme, as this filing only reports a single day's activity within a larger agreement.
- Confirm the impact of the 5.99% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the "Risk Factors" in the 2024 Form 20-F and 2025 Q4 results for context on the company's broader financial health, as this filing does not contain operational metrics.
- Note that the purchase price (approx. £21.79) reflects the market valuation on February 27, 2026.